ABOUT LUPIN U.S. PRESENCE

Lupin U.S. Today

Lupin’s presence in the United States is comprised of a diverse workforce encompassing manufacturing, research and development, and commercial divisions for generics, complex generics, biosimilars and branded pharmaceuticals.

Maintaining a Flagship Generics Stance

Lupin has a strong and well-established generic presence in the United States, having entered the U.S. market in 2003 and maintaining a competitive edge in the list of top 5 generic pharmaceutical companies by prescriptions dispensed since 20101. Our strength in the U.S. generics market is an outgrowth of our multi-channel supply chain, which includes a state-of-the-art U.S. commercial manufacturing facility, robust international distribution, and strategic external partnerships.

Continued Focus on Innovative Product Development to Launch Successful
Brands and First-to-Market Biosimilars

Lupin’s U.S. product development pipeline includes complex inhalation, branded generics projects, and a specialty focus on women’s health. This diversified and productive pipeline helps drive growth across therapeutic areas.

Continued Focus on Innovative Product Development to Launch Successful Brands and First-to-Market Biosimilars

Lupin’s U.S. product development pipeline includes complex inhalation, branded generics projects, and a specialty focus on women’s health. This diversified and productive pipeline helps drive growth across therapeutic areas.

Investment in a Growing Specialty Presence

The launch of SOLOSEC® in 2018 kick-started Lupin’s expansion into the women’s health space, advancing one of our primary business objectives in the United States, which is to bring novel products to the market that address unmet medical needs. Lupin has created a talented, fully integrated Specialty Women’s Health commercial organization in the U.S. in order to build a solid foundation for continued specialty growth in the coming years.

1. IQVIA, National Prescription Audit (Rx), MAT August 2019 Data